Meanwhile, all studied HCV-positive BC patients had a lowered expression level of TTR as compared to the normal controls. X2 analysis indicated that TTR differential expression had significant Axitinib molecular weight variation among the BC patient groups, established on the basis of treatment type and HCV infection. However, no association was found between TTR differential expression and type of breast carcinoma (Table 3). Similarly, we were unable to discriminate BC patients from benign breast disease patients on the basis of TTR differential expression. Expression of modified TTR SEB3 also contained TTR with the same molecular weight and pI but with a different score of peptides match (Table 1). This could be the post-translationally modified proteolytically truncated, cysteinylated and/or glutathionylated form of TTR36 as it migrates as a separate band on SDS-PAGE.

This modified form of TTR was observed in a small fraction of the total cases included in our study. It was not expressed in the HCV-positive BC patients and its expression was slightly higher in the case of infiltrating/invasive duct carcinoma as compared to the other types of breast carcinomas. X2 analysis indicated that expression of the modified TTR does not vary significantly (P > 0.05) among the BC patients and patients of benign breast diseases (Tables 2 and and33). Expression of hemoglobin subunit �� Protein identified from gel band SEB4 is hemoglobin subunit �� and it does not seem to be involved in pathobiology of BC as well as other breast complications.

In the present study, only 1 non-chemotherapeutically treated BC patient and 2 patients suffering from benign breast diseases (ie, 1 mammary dysplasia and 1 fibroadenoma patient) showed elevated levels of this protein (Table 2). Meanwhile, majority of BC and benign breast disease patients were found to have no change in the expression level of this protein. Hence, the expression pattern of hemoglobin subunit �� cannot be considered as the candidate biomarker of BC and benign breast diseases (Table 2). Hemoglobin subunit �� was the part of SEB5 fraction whereas SEB4 is the band cut from the sample BC58 (lane 5, Fig. 2). It may represent a post-translationally modified form of hemoglobin subunit �� that appears as a separate band in few samples. However, in most of the cases, hemoglobin subunit �� was found to be part of SEB5 fraction.

Down-regulation of serum albumin and the complement C4-A containing fraction Serum albumin and the Anacetrapib complement C4-containing fraction (SEB7) was down-regulated in the majority of BC and benign breast disease patients (Table 2). Furthermore, detailed analysis revealed that all groups of BC patients, including treated, HCV infected and type of carcinoma-based groups, had down-regulation of the SEB7 fraction.